Bayer unveils drug for CKD associated with diabetes under brand name Kerendia
The major focus of therapy in patients with chronic kidney disease and diabetes is to prevent end stage renal disease or kidney failure.
New Delhi: Drugmaker Bayer on Thursday said it has introduced a medication for the treatment of chronic kidney disease associated with diabetes under the brand name Kerendia. The drug is a non-steroidal, selective mineralocorticoid receptor antagonist indicated for patients with chronic kidney disease associated with type 2 diabetes.The major focus of therapy in patients with chronic...
New Delhi: Drugmaker Bayer on Thursday said it has introduced a medication for the treatment of chronic kidney disease associated with diabetes under the brand name Kerendia.
The drug is a non-steroidal, selective mineralocorticoid receptor antagonist indicated for patients with chronic kidney disease associated with type 2 diabetes.
Medical Dialogues team had earlier announced that Bayer had received marketing authorization from the Japanese Ministry of Health, Labour, and Welfare (MHLW) for finerenone under the brand name Kerendia.
Read also: Bayer Gets Nod For Kerendia To Treat Type 2 Diabetes, CKD In Japan
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd